|
Panitumumab-IRDye800 Clinical Trials
6 actively recruiting trials across 4 locations
Also known as: Panitumumab IRDye 800, RDye800-Panitumumab Conjugate, panitumumab-IRDye800CW
Pipeline
Phase 1: 1Phase 2: 1Phase 1/2: 4
Top Sponsors
- Stanford University3
- Vanderbilt-Ingram Cancer Center1
- University of Alabama at Birmingham1
- George Poultsides1
Indications
- Cancer6
- Metastatic Malignant Neoplasm in the Lung1
- Malignant Brain Neoplasm1
- Lung Carcinoma1
- Recurrent Head and Neck Squamous Cell Carcinoma1
Palo Alto, California3 trials
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford University, School of Medicine
Phase 1/2
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Stanford University School of Medicine
Phase 1/2
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Stanford University, School of Medicine
Phase 1/2
Birmingham, Alabama1 trial
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
University of Alabama at Birmingham
Phase 2
Stanford, California1 trial
Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures
Stanford Cancer Center
Phase 1/2
Nashville, Tennessee1 trial
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Vanderbilt University/Ingram Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.